Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NAINH

Financiado

Cerrado

The Development of Mechanism Based Inhibitors of Influenza Neuraminidase to targ...

The Development of Mechanism Based Inhibitors of Influenza Neuraminidase to target Drug Induced Resestance The recent emergence of the highly pathogenic H5N1 strain of avian influenza now circulating in Asia, EU and Africa has increased concerns that a new, and devastating, influenza pandemic may be imminent. Antiviral drugs represent... ver más

31/05/2011

UBAH

172K€

Presupuesto del proyecto: 172K€

Líder del proyecto

UNIVERSITY OF BATH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-05-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UBAH

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CATAFLU.OR OrganoCATAlytic approaches towards easily synthesized econo... 3M€ Cerrado

ANTIFLU Innovative anti influenza drugs excluding viral escape 8M€ Cerrado

FLUCURE Development of novel antiviral drugs against Influenza 8M€ Cerrado

PANVIPREP Developing broad-spectrum antiviral drugs for pandemic prepa... 8M€ Cerrado

FLU-PHARM New drugs targeting influenza virus polymerase 8M€ Cerrado

FluAttack Validation of a novel antiviral drug candidate against influ... 150K€ Cerrado

Líder del proyecto

UNIVERSITY OF BATH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 172K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The recent emergence of the highly pathogenic H5N1 strain of avian influenza now circulating in Asia, EU and Africa has increased concerns that a new, and devastating, influenza pandemic may be imminent. Antiviral drugs represent the first line of defence for pandemic outbreaks, and governments are currently stockpiling the influenza neuraminidase inhibitors Relenza® (Zanamivir) and Tamiflu® (Oseltamivir) in preparedness. These neuraminidase inhibitors are highly potent and specific inhibitors against all known influenza A and B strains, including the avian H5N1 virus. There are, however, several problems associated with Relenza and Tamiflu. Unfortunately, as Relenza is only delivered to the respiratory tract, its usefulness is limited if the pandemic influenza strain spreads to other organs, and, more alarmingly, drug-induced resistance to Tamiflu has already been observed in clinical isolates from H5N1 infected patients. As such, there is an urgent need to develop new and improved classes of anti-virals for the treatment of influenza. Dr Watts has recently filed a provisional patent application for the use of fluorinated sialic acid analogues as ‘mechanism-based’ neuraminidase inhibitors for the treatment of influenza. These novel compounds are known to covalently inhibit influenza neuraminidases by specifically targeting amino acid residues essential for catalytic activity and, as such, drug-induced resistance is less likely to evolve in response to these compounds. We propose to synthesise a series of modified fluoro-sialic acids as ‘mechanism-based’ inhibitors of influenza neuraminidases, incorporating structural features designed to improve the pharmacokinetic properties and inhibitory activities of the original inhibitors. We will then perform detailed kinetic analyses of their inhibitory activity against purified influenza neuraminidases, and potent inhibitors will then be tested for efficacy towards a panel of wild-type and drug-resistant influenza viruses.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores